Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0040

Payer / HTA meeting · Dr. Daniel Petit

22 Jan 2026 · In person · Dr. Daniel Petit, Hôpital Pitié-Salpêtrière · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0040—

Capture insight from this engagement

Location: Hôpital Pitié-Salpêtrière
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients

Scientific content used

VOYAGE-1 pivotal data summary
VTX core scientific deck v3.2

Questions raised

What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?
How should grade 2 infusion reactions be managed without steroids?

Notes

Payer / HTA meeting with pathologist at Hôpital Pitié-Salpêtrière. Discussed elderly / ecog 2 patients.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 4
Depth of exchange: 1
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0040

Audit history (0)

All create, update and approval events for this record

No audit events in sample data